Caribou Biosciences presents new data on allogeneic CAR-T cell programs at EHA

Caribou Biosciences presents new data on allogeneic CAR-T cell programs at EHA
Caribou updates on CAR-T data

Caribou Biosciences has presented new data on its allogeneic CAR-T cell programs, targeting lymphoma and multiple myeloma at the EHA congress.

The company continues to advance its pipelines, with the recent discussion during an interview with industry figures underscoring momentum in gene-edited immunotherapies for hematological malignancies.

Caribou Biosciences recently reported longer follow-up dose escalation data for CB-011 in relapsed or refractory multiple myeloma patients, highlighting progress in its cell therapy programs (CB-011 update). Earlier, the company participated in the Jefferies Global Healthcare Conference in New York, with a focus on cell therapy and CRISPR technologies (conference attendance). These developments reflect ongoing activity in Caribou's gene-edited therapeutic pipeline.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.